scholarly journals Type I Interferons and Cancer: An Evolving Story Demanding Novel Clinical Applications

Cancers ◽  
2019 ◽  
Vol 11 (12) ◽  
pp. 1943 ◽  
Author(s):  
Eleonora Aricò ◽  
Luciano Castiello ◽  
Imerio Capone ◽  
Lucia Gabriele ◽  
Filippo Belardelli
Keyword(s):  
Ex Vivo ◽  
Biological Activities ◽  
Mechanisms Of Action ◽  
Added Value ◽  
Type I Interferons ◽  
Interferon Α ◽  
Type I ◽  
Clinical Use ◽  
Antitumor Effects

The first report on the antitumor effects of interferon α/β (IFN-I) in mice was published 50 years ago. IFN-α were the first immunotherapeutic drugs approved by the FDA for clinical use in cancer. However, their clinical use occurred at a time when most of their mechanisms of action were still unknown. These cytokines were being used as either conventional cytostatic drugs or non-specific biological response modifiers. Specific biological activities subsequently ascribed to IFN-I were poorly considered for their clinical use. Notably, a lot of the data in humans and mice underlines the importance of endogenous IFN-I, produced by both immune and tumor cells, in the control of tumor growth and in the response to antitumor therapies. While many oncologists consider IFN-I as “dead drugs”, recent studies reveal new mechanisms of action with potential implications in cancer control and immunotherapy response or resistance, suggesting novel rationales for their usage in target and personalized anti-cancer treatments. In this Perspectives Article, we focus on the following aspects: (1) the added value of IFN-I for enhancing the antitumor impact of standard anticancer treatments (chemotherapy and radiotherapy) and new therapeutic approaches, such as check point inhibitors and epigenetic drugs; (2) the role of IFN-I in the control of cancer stem cells growth and its possible implications for the development of novel antitumor therapies; and (3) the role of IFN-I in the development of cancer vaccines and the intriguing therapeutic possibilities offered by in situ delivery of ex vivo IFN-stimulated dendritic cells.

scholarly journals Multiplexed enrichment and genomic profiling of peripheral immune cell subsets on a microfluidic chip

2018 ◽  
Author(s):  
Miguel Reyes ◽  
Dwayne Vickers ◽  
Kianna Billman ◽  
Thomas Eisenhaure ◽  
Paul Hoover ◽  
...  
Keyword(s):  
Lupus Erythematosus ◽  
Immune Cell ◽  
Ex Vivo ◽  
Response To Therapy ◽  
Added Value ◽  
Type I Interferons ◽  
Type I ◽  
Genomic Profiling ◽  
Diverse Range ◽  
Immune Cell Subsets

ABSTRACTThe human immune system consists of many specialized cell subsets that simultaneously carry out a diverse range of functions using overlapping pathways and signals. Subset-specific immune profiling can resolve immune activity in autoimmune disease, cancer immunity, and infectious disease that may not be discoverable or detectable in analyses of crude blood samples. The activity of specific subsets may help predict the course of disease and response to therapy in certain patient populations. Here, we present a low-input microfluidic system for sorting immune cells into subsets and profiling their cellular states by gene expression analysis using full-length RNA-seq. Our system is robust and has the potential to make multiplexed subset-specific analysis routine in many research laboratories and clinical settings. We validate the device’s technical performance by benchmarking its subset enrichment and genomic profiling performance against standard protocols. We make the added value of subset-resolved profiling over crude samples clear through ex vivo experiments that show subset-specific stimulated responses. Finally, we demonstrate the scalability of our device by profiling four immune cell subsets in blood from systemic lupus erythematosus (SLE) patients and matched controls enrolled in a clinical study. The results from our initial cohort confirm the role of type I interferons in lupus pathogenesis and further show that the canonical interferon signature for SLE is prominent in B cells, demonstrating the ability of our integrated analytical platform to identify cell-specific disease signatures.

The Role of Toll-Like Receptors and Type I Interferons in Host Responses to Bacteria

2009 ◽  
Vol 5 (2) ◽  
pp. 143-149
Author(s):  
Marja Ojaniemi ◽  
Mari Liljeroos ◽  
Reetta Vuolteenaho
Keyword(s):  
Type I Interferons ◽  
Host Responses ◽  
Type I ◽  
Toll Like Receptors

scholarly journals Bacterial Cyclic Dinucleotides and the cGAS–cGAMP–STING Pathway: A Role in Periodontitis?

Pathogens ◽  
2021 ◽  
Vol 10 (6) ◽  
pp. 675
Author(s):  
Samira Elmanfi ◽  
Mustafa Yilmaz ◽  
Wilson W. S. Ong ◽  
Kofi S. Yeboah ◽  
Herman O. Sintim ◽  
...  
Keyword(s):  
Immune Response ◽  
Periodontal Disease ◽  
Innate Immune ◽  
Host Cells ◽  
Type I Interferons ◽  
Type I ◽  
Vaccine Adjuvants ◽  
Cyclic Dinucleotides ◽  
Sting Pathway

Host cells can recognize cytosolic double-stranded DNAs and endogenous second messengers as cyclic dinucleotides—including c-di-GMP, c-di-AMP, and cGAMP—of invading microbes via the critical and essential innate immune signaling adaptor molecule known as STING. This recognition activates the innate immune system and leads to the production of Type I interferons and proinflammatory cytokines. In this review, we (1) focus on the possible role of bacterial cyclic dinucleotides and the STING/TBK1/IRF3 pathway in the pathogenesis of periodontal disease and the regulation of periodontal immune response, and (2) review and discuss activators and inhibitors of the STING pathway as immune response regulators and their potential utility in the treatment of periodontitis. PubMed/Medline, Scopus, and Web of Science were searched with the terms “STING”, “TBK 1”, “IRF3”, and “cGAS”—alone, or together with “periodontitis”. Current studies produced evidence for using STING-pathway-targeting molecules as part of anticancer therapy, and as vaccine adjuvants against microbial infections; however, the role of the STING/TBK1/IRF3 pathway in periodontal disease pathogenesis is still undiscovered. Understanding the stimulation of the innate immune response by cyclic dinucleotides opens a new approach to host modulation therapies in periodontology.

scholarly journals A protective role of IRF3 and IRF7 signalling downstream TLRs in the development of vein graft disease via type I interferons

2017 ◽  
Vol 282 (6) ◽  
pp. 522-536 ◽  
Author(s):  
K. H. Simons ◽  
H. A. B. Peters ◽  
J. W. Jukema ◽  
M. R. de Vries ◽  
P. H. A. Quax
Keyword(s):  
Vein Graft ◽  
Protective Role ◽  
Type I Interferons ◽  
Type I ◽  
Vein Graft Disease ◽  
Graft Disease

The Role of Interferon-α in the Development of Type I Diabetes

1996 ◽  
pp. 154-166
Author(s):  
Xiaojian Huang ◽  
Bruce Hultgren ◽  
Sharon Pitts-Meek ◽  
Jim Hully ◽  
Jim Maclachlan ◽  
...  
Keyword(s):  
Type I Diabetes ◽  
Interferon Α ◽  
Type I

scholarly journals THE ROLE OF TYPE-I INTERFERONS IN POLY I:C INDUCED SICKNESS BEHAVIOUR

2014 ◽  
Vol 8 ◽  
Author(s):  
Murray Carol ◽  
O Loughlin Elaine ◽  
Cunningham Colm
Keyword(s):  
Type I Interferons ◽  
Poly I:C ◽  
Type I ◽  
Sickness Behaviour

The protective role of Toll-like receptor 3 and type-I interferons in the pathophysiology of vein graft disease

2018 ◽  
Vol 121 ◽  
pp. 16-24 ◽  
Author(s):  
K.H. Simons ◽  
M.R. de Vries ◽  
H.A.B. Peters ◽  
J.F. Hamming ◽  
J.W. Jukema ◽  
...  
Keyword(s):  
Vein Graft ◽  
Protective Role ◽  
Type I Interferons ◽  
Type I ◽  
Toll Like Receptor ◽  
Vein Graft Disease ◽  
Graft Disease

Immune response to dermatomyositis-specific autoantigen, transcriptional intermediary factor 1γ can result in experimental myositis

2021 ◽  
pp. annrheumdis-2020-218661
Author(s):  
Naoko Okiyama ◽  
Yuki Ichimura ◽  
Miwako Shobo ◽  
Ryota Tanaka ◽  
Noriko Kubota ◽  
...  
Keyword(s):  
T Cells ◽  
Lymph Node ◽  
Kinase Inhibitor ◽  
Inflammatory Myopathy ◽  
Janus Kinase ◽  
Type I Interferons ◽  
Interferon Α ◽  
Muscle Fibres ◽  
Type I ◽  
Wild Type

ObjectivesTo investigate whether autoimmunity to transcriptional intermediary factor 1 (TIF1)γ, a ubiquitous nuclear autoantigen for myositis-specific autoantibodies detected in patients with dermatomyositis (DM) is pathogenetic for inflammatory myopathy.MethodsWild-type, β2-microglobulin-null, perforin-null, Igμ‐null and interferon α/β receptor (IFNAR)-null mice were immunised with recombinant human TIF1γ whole protein. A thymidine incorporation assay was performed using lymph node T cells from TIF1γ-immunised mice. Plasma was analysed using immunoprecipitation followed by western blot analysis and enzyme-linked immunosorbent assays. Femoral muscles were histologically and immunohistochemically evaluated. CD8+ or CD4+ T cells isolated from lymph node T cells or IgG purified from plasma were adoptively transferred to naïve mice. TIF1γ-immunised mice were treated with anti-CD8 depleting antibody and a Janus kinase inhibitor, tofacitinib.ResultsImmunisation with TIF1γ-induced experimental myositis presenting with necrosis/atrophy of muscle fibres accompanied by CD8+ T cell infiltration successfully in wild-type mice, in which TIF1γ-specific T cells and antihuman and murine TIF1γ IgG antibodies were detected. The incidence and severity of myositis were significantly lower in β₂-microglobulin-null, perforin-null, CD8-depleted or IFNAR-null mice, while Igμ‐null mice developed myositis normally. Adoptive transfer of CD8+ T cells induced myositis in recipients, while transfer of CD4+ T cells or IgG did not. Treatment with tofacitinib inhibited TIF1γ-induced myositis.ConclusionsHere we show that TIF1γ is immunogenic enough to cause experimental myositis, in which CD8+ T cells and type I interferons, but not CD4+ T cells, B cells or antibodies, are required. This murine model would be a tool for understanding the pathologies of DM.

Multiple effects of immunostimulatory DNA on T cells and the role of type I interferons

2001 ◽  
pp. 77-84 ◽  
Author(s):  
Siquan Sun ◽  
Xiaohong Zhang ◽  
David Tough ◽  
Jonathan Sprent
Keyword(s):  
T Cells ◽  
Type I Interferons ◽  
Type I ◽  
Immunostimulatory Dna
Sign in / Sign up

Export Citation Format

Share Document